Print Share Email Twitter Facebook Linkedin Reddit Get Citation Citation Disclaimer: These citations have been automatically generated based on the information we have and it may not be 100% accurate. Please consult the latest official manual style if you have any questions regarding the format accuracy. AMA Citation Bhat S. Bhat S Bhat, Shubha. Ozanimod: A Newly Approved Treatment for Moderate to Severe Ulcerative Colitis. PPP Updates, 6 May 2024. McGraw Hill, 2024. Pharmacotherapy Principles & Practice. https://ppp.mhmedical.com/updatesContent.aspx?gbosid=648485§ionid=286808306APA Citation Bhat S. Bhat S Bhat, Shubha. (2024). Ozanimod: a newly approved treatment for moderate to severe ulcerative colitis. [publicationyear2] Ppp updates. McGraw Hill. https://ppp.mhmedical.com/updatesContent.aspx?gbosid=648485§ionid=286808306.MLA Citation Bhat S. Bhat S Bhat, Shubha. "Ozanimod: A Newly Approved Treatment for Moderate to Severe Ulcerative Colitis." PPP Updates McGraw Hill, 2024, https://ppp.mhmedical.com/updatesContent.aspx?gbosid=648485§ionid=286808306. Download citation file: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Tools Annotate Clip Autosuggest Results Your Access profile is currently affiliated with [InstitutionA] and is in the process of switching affiliations to [InstitutionB]. Please select how you would like to proceed. Keep the current affiliation with [InstitutionA] and continue with the Access profile sign in process Switch affiliation to [InstitutionB] and continue with the Access profile sign in process Get Free Access Through Your Institution Learn how to see if your library subscribes to McGraw Hill Medical products. Subscribe: Institutional or Individual Sign In Error: Incorrect UserName or Password Username Error: Please enter User Name Password Error: Please enter Password Sign in Forgot Password? Forgot Username? Download the Access App: iOS | Android Sign in via OpenAthens Sign in via Shibboleth You already have access! Please proceed to your institution's subscription. Create a free profile for additional features.